BRUTAL Hot Rebound Play which is massive underpriced here trading wayyy below cash Market Cap $43 M / Cash $115 M or untill end 2021 / 2 Marketed Products / 1 Phase 3 trial (common warts) with results expected in Q4 2019 and many other phase 2 programs / because of their strategic change they wants to out-license all their Prodcuts which means HUGE upfront payments for the company (more infos below)= CHEAPEST Biotech you can get at this time could triple easily .. Aclaris Therapeutics (ACRS) Market Cap: $43 M Cash: $115 M or enough untill end 2021 Price: $1.08 Aclaris Therapeutics Announces New Strategic Direction https://investor.aclaristx.com/news...herapeutics-announces-new-strategic-direction ACRS aquired a attractive drug from Allergan last year paid $65 m upfront alone for this drug which they now looking to outlicense . https://www.globenewswire.com/news-...orldwide-Rights-to-RHOFADE-from-Allergan.html Pipeline https://www.aclaristx.com/pipeline/ Largest Shareholders: Deerfield Management Company LP...5 893 416 Franklin Advisers, Inc....3 953 203 BlackRock Fund Advisors ...2 359 223 Broadfin Capital LLC...2 280 260 D. E. Shaw & Co. LP....2 049 462 Sofinnova Ventures, Inc.....1 911 573 Vivo Capital LLC ....1 647 214 Fidelity Management & Research Co...1 562 190 Polar Capital LLP...1 443 920 The Vanguard Group, Inc...1 142 022
the cheapest biotech you can get trading massive under cash who has 2 approved drugs and another phase 3 asset with results expected any day now ... Morgan Stanley reports 5% passive stake in Aclaris Therapeutics...08/29,2019 https://thefly.com/landingPageNews.php?id=2956902 This new strategic direction includes the following actions: Actively Seeking a Commercialization Partner for RHOFADE® (oxymetazoline hydrochloride) cream, 1% Aclaris will also seek strategic partners for ESKATA® (hydrogen peroxide) topical solution, 40% (w/w) Aclaris is actively seeking a strategic partner to commercialize its drug candidate A-101 45% Topical Solution, an investigational compound being developed as a potential treatment for verruca vulgaris (common warts). The Company’s two ongoing Phase 3 pivotal clinical trials, THWART-1 and THWART-2, in which A-101 45% Topical Solution is being evaluated as a potential treatment for common warts, are progressing as planned. Aclaris has completed enrollment of more than 1,000 patients across these two trials, and data from both trials are expected in the second half of 2019. Aclaris is actively seeking a development and commercialization partner for its drug candidates, ATI-501 (oral) and ATI-502 (topical), which are investigational Janus Kinase (JAK) 1/3 inhibitor compounds for the potential treatment of alopecia.
POSITIVEE PHASE 3 RESULTS YIPPIIIIIIIIIIIIIII Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2) https://finance.yahoo.com/news/aclaris-therapeutics-101-45-topical-201540775.html
Exploding in pre mkt up 100% or $2.10 which is still below the $2.80 cash per share ..terrible underpriced
great buying opp again here ,, more news coming shortly like partner deals and second phase 3 readout
if your a shareholder please put a high gtc sell order in $5 or higher .thank you Q:What can you do to prevent your shares holdings from being shorted? A: Now what can the average personal investor do to stop their own shares being shorted, as believe me your own broker, if approached, WILL sell your own shares that they hold on your behalf as a nominee account. There are two things you can do, the first is to certificate them but this is not obviously to everyone’s advantage but the alternative solution is simple. All you do is to phone your broker and put an order in saying that you wish to place your shares for sale at, for arguments sake, double today’s price. As they are ‘on order’ they cannot be lent out by your broker and in turn you are reducing the amount of ‘free shares’ out there that can be used for shorting purposes. And don’t forget to move your limit order up when the price starts to recover, then, that way your shares can’t be shorted – not much but helps . Although an individual personal investor will not normally have enough shares to halt a concerted shorting attack, if a large number of holders did this it would reduce the overall amount of shares that they could get their hands on. In my opinion well worth doing if not only for the knowledge that your own shares cannot and will not be used in a short attack against the very share that you own. https://www.contracts-for-difference.com/Borrowing-lending-shares.html ACRS = Market Cap $57 M / Cash $115 Million or unteill late 2021 EXCLUDING big Upfront payments from partnering for their 5 drugs which expected shortly / 2 APPROVED Drugs / FULL pipeline including a Phase 3 asset with strong results and large market potential / Strong Insider and Institutional ownership...One if not the cheapest Biotech in the Sector .GL
With $115 Million Cash or untill late 2021 and more Cash + Royalties from partnering of their commercial and pipeline assets (expected soon) and approval of the warts drug ACRS could reach profitability and may never needs Cash again IF they can reduce the burn-rate to $10 million or lower per Quarter which is achievable . Whatever this stock is a MEGA BUYING OPP ahead of the second Phase 3 readout and Partnering expected during Q4 .GL Aclaris Therapeutics to Hold R&D Day https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-hold-rd-day Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it will host an R&D day for analysts and investors focused on its pipeline of novel drug candidates for immuno-inflammatory diseases on Friday, September 27, 2019 from 8:00 AM to 11:00 AM in New York, New York.
Eskata approval in Canada expected within 3 Weeks will trigger milestone payment to ACRS and will push stock much higher again .And there is more tocomeduring the Q4like licensing deals and the readout of the second Phase 3 trial .Market Cap $51.5 Million /Cash balance $115 Million Cipher Pharmaceuticals Announces A-101 40% Topical Solution Accepted for Review by Health Canada...Dec. 18, 2018 https://cipher.investorroom.com/201...Solution-Accepted-for-Review-by-Health-Canada A-101 40% is a U.S. Food and Drug Administration ("FDA")-approved product indicated for the treatment of raised SKs, which are commonly occurring non-cancerous skin growths that affect more than 9 million Canadian adults and can be an aesthetic skin concern. About Seborrheic Keratoses SKs are non-cancerous skin growths that affect an estimated 20% of the population and are most commonly seen in middle-aged and older adults. SKs vary in color from flesh-colored to pink, yellow, gray, tan, brown, or black; can range in size from a millimetre to a few centimetres wide; and typically have a slightly elevated, waxy or scaly appearance. The number and size of SKs tends to increase with advancing age. SKs frequently appear in highly visible locations, such as the face or neck, but can also appear anywhere on the body, except the palms, soles and mucous membranes.
With One Late-Stage Study Out Of The Way, Aclaris Moves One Inch Closer To Commercialization https://seekingalpha.com/article/42...laris-moves-one-inch-closer-commercialization
Book Value $3.30 / Cash per Share $2.79 / 2+ years of Cash / 2 Approved Drugs / Another one with strong phase 3 results /Licensing Deals + Eskata approvalaround the corner = GREAT BUYING OPP
What you get for the Market Cap of laughable $42 Million = you get $115 M of Cash or enough untill end 2021 / 2 Approved Drugs for which they own WW rights one of them acquired for $65 Million from Allergan / Another HUGE drug in Phase 3 with strong results in first P3 trial / and many other drugs in Phase 2 trials...the dropping stock markets created a mega opportunity here
Price $1.13 ...Market cap $45 Million ...Cash $115Million ...Book Value $3.30 ...Cash per Share $2.79 = STRONG BUY UPCOMING BIG MILESTONES EXPECTED DURING Q4 Eskata approval could come this or next Week A-101(common warts) final Phase 3 readout within 4-6 weeks ATI-450 (Rheumatoid arthritis) Phase 1 results before year end Partnership(s) for Eskata (approved), Rhofade (approved), A-101 (Phase 3) , ATI-502 (Phase 2) oral & topical could hit the wire anytime now .
